Pfizer is in advanced talks to acquire U.S. cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.
Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi made in April, which eventually resulted in the company putting itself up for sale. Medivation shares ended trading in New Y...
21:17 Lawmakers Change Their Tone on AT&T and Time Warner Deal22
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21
03:00 Carrier incentives stir debate over 'rewarding' offshoring17